The cancer-causing propensity of constitutively activated STAT3 protein and the evidence of potential clinical benefits of blocking constitutive STAT3 signaling make strong arguments for target validity of STAT3 for drug intervention in cancer therapy. The gene discussed is STAT3; the disease is cancer.